Please assess the completion status of the following clinical trial:

Trial Title: Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient with established moderate to severe rheumatoid arthritis~Exclusion Criteria:~* All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment~* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol (CZP) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).